At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 target
Drug / intervention
chemotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of the Safety of CMA-676 in Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) in First Relapse
In Brief
A Phase 2 clinical trial evaluating chemotherapy and gemtuzumab ozogamicin for Leukemia. Completed, enrolled 55 participants across 10 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute myeloid leukemia that has recurred for the first time following at least 3 months of complete remission.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 1998
Primary CompletionMar 1999
First PostedSep 2004
TodayJul 2026
First PostedSep 13, 2004
Enrollment StartMar 1, 1998
Primary CompletionMar 1, 1999
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 21.8 years ago
Interventions
chemotherapydrug
gemtuzumab ozogamicindrug